In this study, the authors showed that patients with AML who received a high-intensity lymphodepleting regimen of cyclophosphamide and fludarabine followed by an infusion of haploidentical, related-donor NK cells with subcutaneous IL-2 resulted in a marked endogenous production of IL-15 and donor NK cell expansion [125]. The gene discussed is IL15; the disease is acute myeloid leukemia.